BR112014007654A2 - inibidores de lrrk2 quinase macrocíclicos. - Google Patents
inibidores de lrrk2 quinase macrocíclicos.Info
- Publication number
- BR112014007654A2 BR112014007654A2 BR112014007654A BR112014007654A BR112014007654A2 BR 112014007654 A2 BR112014007654 A2 BR 112014007654A2 BR 112014007654 A BR112014007654 A BR 112014007654A BR 112014007654 A BR112014007654 A BR 112014007654A BR 112014007654 A2 BR112014007654 A2 BR 112014007654A2
- Authority
- BR
- Brazil
- Prior art keywords
- kinase inhibitors
- lrrk2 kinase
- macrocyclic
- macrocyclic lrrk2
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/18—Bridged systems
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP2011067086 | 2011-09-30 | ||
PCT/IB2012/002318 WO2013046029A1 (en) | 2011-09-30 | 2012-09-28 | Macrocyclic lrrk2 kinase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112014007654A2 true BR112014007654A2 (pt) | 2018-04-17 |
BR112014007654A8 BR112014007654A8 (pt) | 2018-06-12 |
Family
ID=47326223
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014007654A BR112014007654A8 (pt) | 2011-09-30 | 2012-09-28 | Inibidores de lrrk2 quinase macrocíclicos. |
Country Status (18)
Country | Link |
---|---|
US (2) | US9096609B2 (pt) |
EP (1) | EP2760453B1 (pt) |
JP (1) | JP6082397B2 (pt) |
KR (1) | KR20140095477A (pt) |
CN (1) | CN104023728B (pt) |
AU (1) | AU2012314035B2 (pt) |
BR (1) | BR112014007654A8 (pt) |
CA (1) | CA2850350A1 (pt) |
DK (1) | DK2760453T3 (pt) |
ES (1) | ES2583477T3 (pt) |
HK (1) | HK1199838A1 (pt) |
HU (1) | HUE029728T2 (pt) |
MX (1) | MX342177B (pt) |
PL (1) | PL2760453T3 (pt) |
PT (1) | PT2760453T (pt) |
RU (1) | RU2622104C2 (pt) |
UA (1) | UA113186C2 (pt) |
WO (1) | WO2013046029A1 (pt) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9090630B2 (en) * | 2011-09-30 | 2015-07-28 | Oncodesign S.A. | Macrocyclic FLT3 kinase inhibitors |
EP3255049A1 (en) | 2012-06-29 | 2017-12-13 | Pfizer Inc | Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors |
TW201444850A (zh) * | 2013-03-15 | 2014-12-01 | Ipsen Pharma Sas | 巨環lrrk2激酶抑制劑 |
MX2015012528A (es) * | 2013-03-15 | 2016-04-15 | Oncodesign Sa | Inhibidores macrociclicos de cinasa inducibles por sal. |
BR112015022982A2 (pt) * | 2013-03-15 | 2017-07-18 | Oncodesign Sa | inibidores macrocíclicos de rip2 quinase |
WO2014180524A1 (en) * | 2013-05-06 | 2014-11-13 | Merck Patent Gmbh | Macrocycles as kinase inhibitors |
US9695171B2 (en) | 2013-12-17 | 2017-07-04 | Pfizer Inc. | 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors |
WO2015136073A1 (en) * | 2014-03-14 | 2015-09-17 | Oncodesign Sa | Macrocyclic tgf-br2 kinase inhibitors |
US10004751B2 (en) | 2014-07-10 | 2018-06-26 | The J. David Gladstone Institutes | Compositions and methods for treating Dengue virus infection |
EP3194407B1 (en) | 2014-09-17 | 2019-10-23 | Oncodesign S.A. | Macrocyclic rip2 kinase inhibitors |
WO2016042089A1 (en) * | 2014-09-17 | 2016-03-24 | Oncodesign S.A. | Macrocyclic lrrk2 kinase inhibitors |
WO2016146651A1 (en) | 2015-03-16 | 2016-09-22 | Oncodesign Sa | Macrocyclic activin-like receptor kinase inhibitors |
EP3350178B1 (en) | 2015-09-14 | 2021-10-20 | Pfizer Inc. | Novel imidazo [4,5-c]quinoline and imidazo [4,5-c][1,5]naphthyridine derivatives as lrrk2 inhibitors |
SG11201900163PA (en) * | 2016-07-28 | 2019-02-27 | Tp Therapeutics Inc | Macrocycle kinase inhibitors |
SG11201908234WA (en) * | 2017-02-24 | 2019-10-30 | Daegu Gyeongbuk Medical Innovation Found | Pharmaceutical composition comprising compound capable of penetrating blood-brain barrier as effective ingredient for preventing or treating brain cancer |
JP2020526543A (ja) * | 2017-07-14 | 2020-08-31 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | ロイシンリッチリピートキナーゼ2の阻害剤 |
CN110627812B (zh) | 2018-06-25 | 2022-10-11 | 北京诺诚健华医药科技有限公司 | 作为trk抑制剂的杂环化合物 |
MX2021004538A (es) | 2018-10-22 | 2021-09-10 | Esker Therapeutics Inc | Inhibidores de tyk2 y sus usos. |
US20230357269A1 (en) * | 2020-05-06 | 2023-11-09 | Les Laboratoires Servier | New macrocyclic lrrk2 kinase inhibitors |
WO2022194976A1 (en) * | 2021-03-18 | 2022-09-22 | Les Laboratoires Servier | Macrocyclic lrrk2 kinase inhibitors |
WO2023076404A1 (en) | 2021-10-27 | 2023-05-04 | Aria Pharmaceuticals, Inc. | Methods for treating systemic lupus erythematosus |
WO2023073013A1 (en) * | 2021-10-27 | 2023-05-04 | H. Lundbeck A/S | Lrrk2 inhibitors |
CN117425660A (zh) * | 2022-05-18 | 2024-01-19 | 上海翊石医药科技有限公司 | 一种芳杂环类化合物及其中间体、药物组合物和用途 |
WO2023224894A1 (en) * | 2022-05-20 | 2023-11-23 | Merck Sharp & Dohme Llc | Macrocycles as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IS2334B (is) | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
ATE209903T1 (de) | 1993-10-01 | 2001-12-15 | Astrazeneca Ab | Verfahren i |
EP0729758A3 (en) | 1995-03-02 | 1997-10-29 | Pfizer | Pyrazolopyrimidines and pyrrolopyrimidines to treat neuronal disorders and other diseases |
US6043358A (en) | 1995-11-01 | 2000-03-28 | Merck & Co., Inc. | Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases |
EP1908764A1 (en) | 1996-07-24 | 2008-04-09 | Bristol-Myers Squibb Pharma Company | Azolo triazines and pyrimidines |
GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
US6194410B1 (en) | 1998-03-11 | 2001-02-27 | Hoffman-La Roche Inc. | Pyrazolopyrimidine and pyrazolines and process for preparation thereof |
US6369087B1 (en) | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
ATE526330T1 (de) | 2000-12-28 | 2011-10-15 | Ono Pharmaceutical Co | Heterotrizyklische verbindungen als antagonisten des crf-rezeptors |
DE10239042A1 (de) * | 2002-08-21 | 2004-03-04 | Schering Ag | Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel |
AU2004298448B2 (en) * | 2003-12-18 | 2010-09-09 | Janssen Pharmaceutica N.V. | Pyrido- and pyrimidopyrimidine derivatives as anti- proliferative agents |
DK1802749T3 (da) | 2004-10-21 | 2012-11-26 | Mayo Foundation | KASPP (LRRK2)-gen, dets fremstilling og anvendelse til påvisning og behandling af neurodegenerative lidelser |
NO323175B1 (no) | 2004-12-23 | 2007-01-15 | Jan O Aasly | Framgangsmate for a pavise en mutasjon som forarsaker arvelig parkinsonisme |
FI123725B (fi) | 2005-08-01 | 2013-10-15 | Reijo Viljanen | Menetelmä sahalaitteen terän jännittämiseksi ja ohjaamiseksi sekä ohjaus- ja jännityslaitteet |
DE102005042742A1 (de) * | 2005-09-02 | 2007-03-08 | Schering Ag | Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
US7750000B2 (en) * | 2005-09-02 | 2010-07-06 | Bayer Schering Pharma Ag | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments |
BRPI0618552B8 (pt) * | 2005-11-16 | 2021-05-25 | Cell Therapeutics Inc | compostos derivados de pirimidina ligados ao oxigênio,composição farmacêutica que inclui os ditos compostos,método de síntese dos compostos e usos terapêuticos dos mesmos |
MX2009004700A (es) * | 2006-11-06 | 2009-05-15 | Supergen Inc | Derivados de imidazo[1,2-b]piridazin y pirazolo[1,5-a] pirimidina y su uso como inhibidores de proteina cinasa. |
WO2008060248A1 (en) * | 2006-11-15 | 2008-05-22 | S*Bio Pte Ltd. | Indole sustituted pyrimidines and use thereof in the treatment of cancer |
AU2007335962B2 (en) * | 2006-12-20 | 2012-09-06 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Antiviral indoles |
US7732434B2 (en) * | 2007-04-20 | 2010-06-08 | Bristol-Myers Squibb Company | Macrocyclic acyl guanidines as beta-secretase inhibitors |
EP2185562B1 (en) * | 2007-07-27 | 2015-12-02 | Janssen Pharmaceutica, N.V. | Pyrrolopyrimidines useful for the treatment of proliferative diseases |
AU2009224804B2 (en) * | 2008-03-10 | 2013-12-05 | Janssen Pharmaceutica Nv | 4-aryl-2-anilino-pyrimidines as PLK kinase inhibitors |
DE102008019146A1 (de) | 2008-04-16 | 2009-11-05 | Airbus Deutschland Gmbh | Enteisungssystem für ein Flugzeug |
RU2011142182A (ru) * | 2009-03-19 | 2013-04-27 | Медикал Рисерч Каунсил Текнолоджи | Соединения |
RU2012116003A (ru) * | 2009-09-21 | 2013-10-27 | Ф.Хоффманн-Ля Рош Аг | Макроциклические ингибиторы jak |
KR20120081609A (ko) | 2009-09-29 | 2012-07-19 | 글락소 그룹 리미티드 | 신규 화합물 |
CN103748099B (zh) * | 2011-05-19 | 2016-08-17 | 卡洛斯三世国家癌症研究中心基金会 | 作为蛋白激酶抑制剂的大环化合物 |
WO2013001310A1 (en) * | 2011-06-30 | 2013-01-03 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Macrocyclic compounds and their use as cdk8 inhibitors |
US9090630B2 (en) * | 2011-09-30 | 2015-07-28 | Oncodesign S.A. | Macrocyclic FLT3 kinase inhibitors |
-
2012
- 2012-09-28 HU HUE12798824A patent/HUE029728T2/en unknown
- 2012-09-28 ES ES12798824.4T patent/ES2583477T3/es active Active
- 2012-09-28 KR KR1020147011284A patent/KR20140095477A/ko not_active Application Discontinuation
- 2012-09-28 US US14/348,138 patent/US9096609B2/en not_active Expired - Fee Related
- 2012-09-28 MX MX2014003557A patent/MX342177B/es active IP Right Grant
- 2012-09-28 UA UAA201404562A patent/UA113186C2/uk unknown
- 2012-09-28 DK DK12798824.4T patent/DK2760453T3/en active
- 2012-09-28 WO PCT/IB2012/002318 patent/WO2013046029A1/en active Application Filing
- 2012-09-28 JP JP2014532498A patent/JP6082397B2/ja not_active Expired - Fee Related
- 2012-09-28 PT PT127988244T patent/PT2760453T/pt unknown
- 2012-09-28 CN CN201280058430.8A patent/CN104023728B/zh not_active Expired - Fee Related
- 2012-09-28 AU AU2012314035A patent/AU2012314035B2/en not_active Ceased
- 2012-09-28 BR BR112014007654A patent/BR112014007654A8/pt not_active IP Right Cessation
- 2012-09-28 PL PL12798824.4T patent/PL2760453T3/pl unknown
- 2012-09-28 CA CA2850350A patent/CA2850350A1/en not_active Abandoned
- 2012-09-28 RU RU2014117515A patent/RU2622104C2/ru not_active IP Right Cessation
- 2012-09-28 EP EP12798824.4A patent/EP2760453B1/en not_active Not-in-force
-
2015
- 2015-01-14 HK HK15100389.2A patent/HK1199838A1/xx not_active IP Right Cessation
- 2015-06-23 US US14/747,882 patent/US9370520B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU2012314035A1 (en) | 2014-05-15 |
US9370520B2 (en) | 2016-06-21 |
PL2760453T3 (pl) | 2016-11-30 |
CN104023728A (zh) | 2014-09-03 |
HK1199838A1 (en) | 2015-07-24 |
CN104023728B (zh) | 2016-11-02 |
RU2622104C2 (ru) | 2017-06-13 |
HUE029728T2 (en) | 2017-03-28 |
EP2760453A1 (en) | 2014-08-06 |
WO2013046029A1 (en) | 2013-04-04 |
EP2760453B1 (en) | 2016-05-25 |
US20140206683A1 (en) | 2014-07-24 |
DK2760453T3 (en) | 2016-08-15 |
JP2014528405A (ja) | 2014-10-27 |
MX2014003557A (es) | 2014-11-26 |
JP6082397B2 (ja) | 2017-02-15 |
ES2583477T3 (es) | 2016-09-21 |
UA113186C2 (xx) | 2016-12-26 |
KR20140095477A (ko) | 2014-08-01 |
PT2760453T (pt) | 2016-08-02 |
RU2014117515A (ru) | 2015-11-10 |
AU2012314035B2 (en) | 2016-12-15 |
US20150290198A1 (en) | 2015-10-15 |
US9096609B2 (en) | 2015-08-04 |
CA2850350A1 (en) | 2013-04-04 |
MX342177B (es) | 2016-09-20 |
BR112014007654A8 (pt) | 2018-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014007654A2 (pt) | inibidores de lrrk2 quinase macrocíclicos. | |
CO6970602A2 (es) | Inhibidores de quinasa | |
BR112013030095A2 (pt) | inibidores de atividade de lrrk2 cinase | |
DK2710007T3 (da) | Kinasehæmmere | |
BR112014000653A2 (pt) | inibidores de tirosina quinase de bruton | |
BR112013029620A2 (pt) | inibidores de tirosina quinase de bruton | |
CO6950481A2 (es) | Inhibidores de proteínas quinasas | |
DK2903618T3 (da) | Rho-kinase-inhibitorer | |
CO6801749A2 (es) | Inhibidores de glucosilceramida sintasa | |
BR112014003214A2 (pt) | polimorfos inibidores de cinase | |
BR112014010784A2 (pt) | pesquisa de determinação de espaço. | |
CO6880068A2 (es) | Aminoquinazolinas como inhibidores de quinasa | |
EP2782580A4 (en) | SELECTIVE INHIBITORS OF KINASES | |
CO6862145A2 (es) | Imidazopiridazinas como inhibidores de quinasa akt | |
CO6990735A2 (es) | Inhibidores de pirazina cinasa | |
IL229028A0 (en) | Kinase inhibitors | |
CO6890101A2 (es) | Inhibidores de pde10 de pirimidina | |
HK1199873A1 (en) | Kinase inhibitors | |
HK1219481A1 (zh) | 大環的 激酶抑制劑 | |
FR2978994B1 (fr) | . | |
ES2397885B1 (es) | Derivados de colismicina. | |
FR2980994B1 (fr) | Prehenseur multi-plaquettes. | |
ITRM20110115U1 (it) | Gruppo erogatore. | |
ITMI20121467A1 (it) | Gruppo mortasatore | |
ES1074539Y (es) | Mandil. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B25L | Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled |
Owner name: ONCODESIGN S.A. (FR) |
|
B25A | Requested transfer of rights approved |
Owner name: ONCODESIGN S.A. (FR) |
|
B25L | Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled |
Owner name: ONCODESIGN S.A. (FR) |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2481 DE 24-07-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |